Objective. Inflammatory back pain (IBP) is often an early manifestation of spondyloarthritis (SpA), but the prognosis of patients with incident IBP is unknown. This study was undertaken to investigate long-term outcomes in patients with IBP, and predictors of progression to SpA, in a population-based cohort.
2009-2010 National Health and Nutrition Examination
Survey (NHANES) (9) . In contrast, the prevalence of SpA is estimated to range from 0.4% to 1.3% (10, 11) . This gap between the prevalence of IBP (the symptom) and the prevalence of SpA (the disease) is unexplained. It could mean that IBP features are common components of back pain due to many different disorders, and that the IBP criteria are less specific when applied to the general population. Alternatively, it could indicate that a substantial number of patients with IBP have inflammatory symptoms that do not evolve to AS or SpA. Although several reports have described the clinical evolution in patients with possible AS or undifferentiated SpA, no studies have specifically examined long-term outcomes in patients with IBP who do not necessarily have other SpA features (12) (13) (14) .
To address these questions, study of an inception cohort of patients with IBP with a long follow-up is needed, given that it may take up to 10 years from symptom onset to diagnosis of SpA (15) . In addition, the study should include patients who present to primary care as well as many diverse specialties, given that many types of providers care for patients with back pain. Therefore, we conducted a retrospective longitudinal study of a population-based cohort from the Rochester Epidemiology Project (REP). Our goal was to determine long-term clinical outcomes in patients with new-onset IBP, and specifically to determine the proportion in whom IBP progressed to a clinical diagnosis of SpA. Finding that IBP progressed to SpA in a large proportion of patients would support the notion that IBP and SpA are tightly linked processes. Alternatively, finding that IBP progressed to conditions other than SpA in many patients would suggest limited specificity of IBP symptoms for a diagnosis of SpA. Finding that IBP resolved in many patients would indicate that IBP can be a self-limited problem. We also sought to identify whether there were subgroups of patients who, based on demographic or clinical characteristics, were more likely to experience progression to SpA.
PATIENTS AND METHODS
Data source and patient inclusion. The REP is a medical record-linkage system with longitudinal medical data on the complete population of Olmsted County, MN (108,095 persons in 2000), with a 98% participation rate in 2000 (16) . Medical records from all subspecialties are included, which is particularly important in a retrospective study of IBP. Diagnoses and symptoms present at each visit are extensively coded using both International Classification of Diseases, Ninth Revision (ICD-9) and Hospital International Classification of Diseases Adaptation (HICDA) codes. This study was approved by the institutional review boards of the Mayo Clinic and Olmsted Medical Center, Rochester, MN.
We included Olmsted County residents who had newly identified IBP at an age of 16-35 years between January 1, 1999 and December 31, 2003. These years were chosen because electronic medical records (EMRs) were adopted in 1999, and to allow for at least 12 years of follow-up. Our operational definition of IBP was fulfillment of any 1 of the 3 IBP criteria sets (Calin, Berlin, or ASAS) based on medical record review, or notation of the presence of IBP by a treating rheumatologist (even if the patient did not fulfill any of the 3 criteria sets) (4) (5) (6) .
Case ascertainment and data collection. We used 3 steps to identify patients with new-onset IBP: 1) electronic searches of medical records for relevant diagnosis and procedure codes, 2) screening of EMRs of potentially eligible back pain visits for implicit diagnosis of IBP, and 3) detailed chart review of those who screened positive for IBP on implicit review to apply explicit IBP criteria. Data are available upon request from the corresponding author.
Specifically, we started with a search for patients ages 16-35 years with a diagnosis of back pain in 2000-2003, using ICD-9 codes and HICDA codes for back pain. A complete list of codes is available upon request from the corresponding author. We excluded patients who had a back pain visit and a diagnosis code for external causes of injury and poisoning (E-code) on the same day, patients who had a back pain visit and a code for pregnancy on the same day, and patients with diagnosis codes for sciatica (ICD-9 724.3) or lumbosacral neuritis (ICD-9 724.4) and a procedure code for laminectomy/discectomy within 1 year of either of these diagnoses. These exclusions were based on preliminary chart reviews that showed that these patients had very low likelihoods of having IBP. Additionally, in preliminary work, the yield of cases of incident IBP was much lower among patients older than 35 years, so we set this as the maximum age at onset for this study.
The initial search identified 5,304 patients who had a medical visit for back pain (not necessarily new-onset back pain) in 2000-2003, at age 16-35. Two rheumatologists (RW and MMW) reviewed the medical records for these back pain visits, and each patient was classified as having "no IBP," "possible IBP," or "definite IBP" based on the reviewers' impression of back pain descriptions. Charts of all patients with "possible IBP" or "definite IBP" were reviewed and confirmed by both reviewers. To ensure the specificity of our cohort, a third rheumatologist (KW) who was not involved in the initial screening also reviewed the records of patients who had been classified as having "possible IBP" and "definite IBP" to confirm or refute the presence of IBP. One investigator (RW) undertook a detailed chart review of the records of patients who had "possible IBP" or "definite IBP."
To identify incident cases, we then identified those who had no back pain visits before January 1, 1999, and who fulfilled our operational definition of IBP, as the inception cohort of patients with IBP. The date that the patient first fulfilled the IBP definition was defined as the IBP incidence date. We also collected demographic information, data on SpA-related clinical features, clinical diagnosis, and laboratory results, including the presence or absence of markers of inflammation and HLA-B27 status, through follow-up until the end of data collection on July 31, 2016. Clinical SpA features included a history of uveitis, peripheral arthritis, psoriasis, dactylitis, enthesitis, inflammatory bowel disease, or reactive arthritis, good response to nonsteroidal antiinflammatory drugs, and family history of SpA, as recorded in the medical records. Clinical features that were not described or documented in the medical records were considered absent. HLA-B27 was not tested in all patients, and was categorized as positive, negative, or unknown.
The primary outcome was the development of SpA, including either AS according to the modified New York criteria or a clinical diagnosis of SpA, psoriatic arthritis, inflammatory bowel disease-associated arthritis, or reactive arthritis by the treating rheumatologist. Given that all patients satisfied the clinical criterion for IBP, AS was defined as the presence of bilateral grade 2 or unilateral grade 3 or 4 sacroiliitis based on a review of all available pelvis, hip, lumbar spine, and abdominal radiographs by one reader (MMW) (2) . Diagnoses other than SpA that explained the patient's back pain symptoms, such as degenerative spine conditions and fibromyalgia, were recorded as well.
For patients who developed SpA, the outcome date was defined as the date of a clinical diagnosis of SpA or the date of the first radiographs that showed sacroiliitis, whichever occurred first. For patients diagnosed as having non-SpA conditions, the outcome date was the date of non-SpA diagnosis. Patients who received no specific diagnosis for their back pain during followup were categorized into 1 of 2 outcome groups: 1) those who continued to report back pain on visits within 1 year of their last recorded medical visit were defined as having persistent IBP without a diagnosis of SpA, and 2) those whose back pain was recorded as resolved at a medical visit and did not later recur, or whose last medical visit on which back pain was reported was >1 year prior to their last recorded medical visit, were defined as having IBP resolved. For those whose back pain resolved, the outcome date was the date of the visit documenting the resolution of back pain; when this was not recorded, the midpoint between the date of the last medical visit with back pain and the date of the last medical visit was used. The remaining patients, whose IBP was persistent without a specific diagnosis throughout follow-up, were censored at their last medical visit. If a patient had both SpA and a non-SpA diagnosis, we designated SpA as the outcome, regardless of whether the non-SpA diagnosis preceded the SpA diagnosis.
Statistical analysis. Descriptive statistics were used to summarize the data. Aalen-Johansen methods, a multistate generalization of cumulative incidence with adjustment for competing risks, were used to examine the progression to 3 outcomes: SpA, a specific non-SpA diagnosis, or resolution of IBP (17) .
We performed 2 sensitivity analyses. The first sensitivity analysis included patients who were considered to have "possible IBP" or "definite IBP" by all 3 reviewers and fulfilled the explicit IBP definition. The second sensitivity analysis used the date of onset of back pain, rather than the date of fulfillment of IBP criteria, as the start date for the analysis. In some patients, the reported onset of back pain was months, or occasionally years, earlier than the time when IBP was documented in the medical records, and the time of onset of back pain may reflect the true start of IBP.
We used recursive partitioning methods and Cox proportional hazards models with a time-to-event outcome to identify predictors of progression to SpA. Recursive partitioning identifies predictors that best segregate subgroups with different prognoses. Through its hierarchical tree structure, the method also identifies interactions between predictors that are prognostically influential. Demographic features, clinical SpA features, inflammatory markers, and HLA-B27 status were used as potential predictors in these analyses. Tenfold cross-validation was used to prune the tree by applying a 1 minus standard error 
RESULTS
Study cohort. Of 5,304 Olmsted County residents who had clinical visits for back pain at ages 16-35 years, 172 patients had "possible IBP" or "definite IBP" on implicit review (data are available upon request from the corresponding author). After detailed medical record review, 124 patients with new-onset IBP were identified (2.3% of all patients with visits for new back pain) ( Table 1 ). There were 82 men and 42 women in the cohort. The mean AE SD age at inclusion was 27.8 AE 5.0 years. The mean AE SD age at onset of back pain was 25.0 AE 5.5 years. Ninety-two percent of the cohort fulfilled the Calin criteria, 28% fulfilled the Berlin criteria, and 48% fulfilled the ASAS criteria for IBP. Twenty-nine patients (23%) were evaluated at least once by a rheumatologist. In fourteen patients (11%), IBP was explicitly documented by the treating rheumatologist, and 1 of these patients did not fulfill any of the IBP criteria sets. The median duration of follow-up of the cohort was 13.2 years (interquartile range 8.9-14.6 years). The median number of follow-up pelvis or spine radiographs was 2 (range 1-6).
Progression to SpA. At the end of the follow-up period, IBP had progressed to SpA in 39 patients, including 33 patients with AS based on radiographic sacroiliitis and 6 with SpA based on clinical diagnosis by the treating rheumatologist. In 15 patients IBP evolved to non-SpA conditions, including degenerative disc conditions in 9, fibromyalgia in 3, mechanical back pain in 2, and systemic lupus erythematosus in 1 patient. In 58 patients IBP resolved during the follow-up period. Five patients were censored because of loss to follow-up.
The cumulative probabilities that IBP had evolved to SpA at 5, 10, and 15 years were 24% (95% confidence interval [95% CI] 16-31), 30% (95% CI 21-37), and 33% (95% CI 24-42), respectively ( Figures 1A and B) . The cumulative probabilities that IBP had evolved to a specific non-SpA diagnosis at 5, 10, and 15 years were 11% (95% CI 5-16), 11% (95% CI 5-16), and 13% (95% CI 6-19), respectively. The cumulative probabilities that symptoms of IBP had resolved at 5, 10, and 15 years were 19% (95% CI 12-26), 43% (95% CI 34-52), and 49% (95% CI 39-57), respectively. Of note, within the first year of inclusion, the probability of evolving to SpA was 24% (95% CI 16-31%), and the probability of evolving to a non-SpA diagnosis was 6% (95% CI 2-11%). Results were similar in the sensitivity analysis that included patients who were classified as having IBP by all 3 reviewers (data are available upon request from the corresponding author). In the sensitivity analysis in which follow-up started at the time of back pain onset, the cumulative probabilities that IBP had evolved to SpA at 5, 10, and 15 years were 20% (95% CI 12-26), 27% (95% CI 19-35), and 31% (95% CI 22-38), respectively (Figures 2A and B) . The cumulative probabilities that IBP had evolved to a specific non-SpA diagnosis at 5, 10, and 15 years were 7% (95% CI 2-11), 11% (95% CI 5-16), and 12% (95% CI 6-17), respectively. The cumulative probabilities that IBP had resolved at 5, 10, and 15 years were 15% (95% CI 8-21), 36% (95% CI 27-44), and 43% (95% CI 33-51), respectively.
Predictors of progression to SpA. Recursive partitioning identified a history of uveitis, male sex, and family SpA, those who were tested for HLA-B27 had a 3-fold higher risk of progression to SpA compared to those who were not tested (HR 3.1 [95% CI 1.2-8.1]).
The absolute risk of having developed SpA 5 years after the onset of IBP ranged from 69% for those with a history of uveitis to 8% for women with no history of uveitis. Risks in other subgroups were intermediate. Other clinical features, such as peripheral arthritis, enthesitis, dactylitis, and inflammatory bowel disease, were not identified as prognostically important.
DISCUSSION
Despite the widespread use of IBP in the diagnosis of SpA, little is known about long-term outcomes in patients with IBP. In this population-based study, we found that IBP progressed to SpA in fewer than one-third of the patients during a follow-up period of >13 years. IBP symptoms resolved in almost one-half of the patients. In our cohort, a history of uveitis was the most important predictor of whether a patient was likely to experience progression to SpA.
The finding that IBP resolved without progression in a large proportion of patients suggests that the symptom complex described by IBP may often reflect a self-limited process. This could represent inflammation that is either not intense enough or not sustained enough to result in established SpA. In this way, IBP should be considered analogous to arthralgia, which may not always be associated with objective arthritis. It could also suggest that IBP is associated with a broader differential diagnosis than solely SpA. In many patients, IBP persisted for several years before resolving, suggesting that inflammation was not always transient.
Alternatively, patients without a true inflammatory cause of back pain may have also reported symptoms of IBP, in part because the language describing morning stiffness and changes with activity or rest can be imprecise (18) . Clinicians and patients may interpret and discuss these concepts differently. These patients may have gone on to either be diagnosed with a specific non-SpA disease or have their back pain resolve. Some misclassification could occur due to the limited specificity of the construct or the words used to describe IBP.
Several surveys have been conducted to describe the prevalence of IBP in general populations. In a study conducted in the UK, 20% of patients with back pain fulfilled the Calin criteria for IBP; among them, only 5% had radiographic sacroiliitis (19) . In another UK population-based survey, the prevalence of IBP in patients who presented to their primary care provider with back pain ranged from 7.7% to 15.4%, depending on the criteria used (20) . The prevalence of IBP in Mexico was estimated at 3.0% (21) . In the 2009-2010 NHANES, the prevalence of IBP ranged from 5.0% to 6.0%, depending on the criteria used (9) , while the estimated prevalence of SpA in the US is 1.0% (10) . Our finding that in the majority of patients IBP does not progress to SpA explains this gap between the prevalence of IBP and that of SpA.
Uveitis was the most important predictor of the development of SpA in this cohort, a finding consistent with the results of a previous study (8) . Up to 50% of patients with AS have at least 1 episode of uveitis during the course of their disease (22) . Genetic studies of AS and uveitis have shown shared associations with HLA-B27, as well as IL23R, ERAP1, and the intergenic locus 2p15 (23). In addition, sex and family history also played a role in predicting progression to SpA in patients with IBP. These findings are consistent with the notion that the risk of developing SpA is largely genetically determined. The results also indicate that not all SpA-associated features are equally predictive of progression, and weighting of different features may be useful for this purpose.
In our main analysis, there was a steep increase in SpA at the time patients met the IBP criteria. It is likely that patients had some IBP symptoms for years, and at the time of their initial visit, both IBP and a diagnosis of SpA were identified simultaneously. Because of the design of this study, in which patients were assessed only when they presented for a medical visit rather than at prespecified time intervals, this analysis may have misspecified the true onset of IBP. We addressed this issue in a sensitivity analysis that used the onset of back pain as time 0, which showed a more gradual progression to SpA.
This study had several limitations due to its retrospective nature. We emphasized specificity in the patients who were included, and likely omitted some cases in which the treating physician failed to recognize or document the presence of IBP features. Misclassification of these patients may have occurred because the patients had less typical or prominent IBP symptoms, and may have been even less likely to experience progression to SpA than patients with typical or prominent IBP symptoms. Patient follow-up was based on clinical need, so those with milder symptoms may not have been reevaluated as frequently. This could have resulted in an underestimation of the progression to SpA. In addition, over time, patients may accommodate to their back pain symptoms, and it may not have remained an active issue during clinical encounters. This could lead to an overestimation of resolution. In the analysis of predictors of progression, we considered any undocumented clinical feature as not present, which could lead to an underrecognition of some risk factors. Only 31% of patients were tested for HLA-B27, and diagnostic suspicion bias likely contributed to the prognostic importance of the results related to HLA testing. If HLA testing had been done universally, the predictors of progression might have been different. We did not find peripheral arthritis, enthesitis, dactylitis, or inflammatory bowel disease to be prognostically important; however, the sample size in our study may not be large enough to examine these conditions. Medication history was not included in our analysis. These limitations are balanced by the strengths of the study, which is the first population-based study of outcomes in patients with IBP. We also had the advantage of accessing complete medical records over an extended time, which allowed tracking of clinical outcomes.
Our findings indicate that while IBP can be a precursor of SpA, the presence of IBP does not predestine patients to develop SpA. IBP is more accurately considered a symptom complex of a specific type of arthralgia that may or may not be associated with SpA and may be self-limited. Therefore, caution should be taken to not overinterpret the implications of IBP for diagnosis, and to seek objective findings and other aspects of the medical history when counseling patients regarding their prognosis for progression to SpA.
